<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="15072">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02060708</url>
  </required_header>
  <id_info>
    <org_study_id>1000042023</org_study_id>
    <nct_id>NCT02060708</nct_id>
  </id_info>
  <brief_title>Determining the Specificity of High Definition Electrical Brain Stimulation Using Simultaneous Magnetoencephalography</brief_title>
  <official_title>Measuring the Stimulated Brain: Determining the Specificity of High Definition Electrical Brain Stimulation Using Simultaneous Magnetoencephalography</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Hospital for Sick Children</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Hospital for Sick Children</source>
  <oversight_info>
    <authority>Canada: Health Canada</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Non-invasive human brain stimulation using weak transcranial direct‐current stimulation
      (tDCS) has been thousands of times in research studies over the past fifteen years as a
      therapy to help improve the effectiveness of repeated training sessions (e.g., hand
      exercises in the context of daily physiotherapy), due to its safety, tolerability,
      convenience and cost‐effectiveness. tDCS works by temporarily enhancing brain activity
      during performance of a specific task, helping with learning and training.

      The investigators will use magnetoencephalography (MEG) brain imaging to view the real‐time
      effects of high definition (HD) tDCS on several brain areas involved in vision, hearing,
      movement, and memory.    The investigators hypothesize that changing the task (auditory,
      visual or memory task) but keeping the position of the electrodes over the motor cortex will
      result in modulation of brain activity in only the central target motor area, and not on
      non-target temporal, occipital or pre-frontal areas.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>May 2014</start_date>
  <primary_completion_date type="Anticipated">May 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change from baseline in brain activity</measure>
    <time_frame>Immediate (20 minutes)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assessment of changes in brain activity will be done using both event-related and frequency domain beam former localization.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Real HD-tDCS</condition>
  <condition>Sham HD-tDCS</condition>
  <condition>Visual Task</condition>
  <condition>Motor Task</condition>
  <condition>Auditory Task</condition>
  <condition>Working Memory Task</condition>
  <arm_group>
    <arm_group_label>Real HD-tDCS first, Sham HD-tDCS second</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Real HD-tDCS will be applied in the first session Sham HD-tDCS will be applied in the second session (at least one week after the first session)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham HD-tDCS first, Real HD-tDCS second</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Sham HD-tDCS will be applied in the first session Real HD-tDCS will be applied in the second session (at least one week after the first session)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>HD-tDCS</intervention_name>
    <description>HD-tDCS non-invasive brain stimulation using this same device (Soterix) has been designated a 'non-significant risk' by the US FDA.</description>
    <arm_group_label>Real HD-tDCS first, Sham HD-tDCS second</arm_group_label>
    <arm_group_label>Sham HD-tDCS first, Real HD-tDCS second</arm_group_label>
    <other_name>High Definition Transcranial Direct Current Stimulation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Normal hearing and vision

        Exclusion Criteria:

          -  Current pregnancy

          -  Presence of metallic implants in the head

          -  Use of any medications

          -  Any history of mental health or neurological conditions

          -  Inability to perform any of the tasks for any reason
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5J0A6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cecilia Jobst, MSc</last_name>
      <phone>416-813-7654</phone>
      <phone_ext>301045</phone_ext>
      <email>cecilia.jobst@sickkids.ca</email>
    </contact>
    <contact_backup>
      <last_name>Sabah Master, PhD</last_name>
      <phone>416-813-7654</phone>
      <phone_ext>301045</phone_ext>
      <email>sabah.master@sickkids.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Douglas Cheyne, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sabah Master, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 10, 2014</lastchanged_date>
  <firstreceived_date>February 6, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Hospital for Sick Children</investigator_affiliation>
    <investigator_full_name>Douglas Cheyne</investigator_full_name>
    <investigator_title>Senior Scientist and Associate Professor, Diagnostic Imaging</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
